» Articles » PMID: 39765236

Managing Stimulant Use Among People With HIV: Harm-Reduction Strategies From Behavior to Medication

Overview
Journal Top Antivir Med
Date 2025 Jan 7
PMID 39765236
Authors
Affiliations
Soon will be listed here.
Abstract

Stimulant use disorder poses substantial challenges to the health and well-being of people with HIV, contributing to increased HIV transmission risk and poor clinical outcomes. This article highlights the cultural significance of stimulant use, its epidemiology, and the latest evidencebased interventions for stimulant use disorder among individuals with HIV. Contingency management has emerged as the most effective treatment, with harm-reduction approaches serving as vital tools for improving the health of individuals unable or unwilling to achieve abstinence. Integrated care models that combine behavioral interventions, pharmacotherapy, and harm reduction offer a promising framework to improve health outcomes for people with HIV who use stimulants, addressing the intersection of stimulant use and HIV in care settings.

References
1.
Griffith J, Roark R, SIMPSON D . Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000; 58(1-2):55-66. DOI: 10.1016/s0376-8716(99)00068-x. View

2.
Li M, Chau B, Garland W, Oksuzyan S, Weiss R, Takada S . Racial, gender, and psychosocial disparities in viral suppression trends among people receiving coordinated HIV care in Los Angeles County. AIDS. 2023; 37(9):1441-1449. PMC: 10330081. DOI: 10.1097/QAD.0000000000003578. View

3.
Goodman-Meza D, Shoptaw S, Weiss R, Nakazono T, Harawa N, Takada S . Methamphetamine use drives decreases in viral suppression for people living with HIV released from a large municipal jail: Results of the LINK LA clinical trial. Drug Alcohol Depend. 2019; 202:178-184. PMC: 6686887. DOI: 10.1016/j.drugalcdep.2019.05.007. View

4.
Kidd J, Smiley S, Coffin P, Carmody T, Levin F, Nunes E . Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder. Drug Alcohol Depend. 2023; 250:110899. PMC: 10530262. DOI: 10.1016/j.drugalcdep.2023.110899. View

5.
Colfax G, Santos G, Das M, Santos D, Matheson T, Gasper J . Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011; 68(11):1168-75. PMC: 3437988. DOI: 10.1001/archgenpsychiatry.2011.124. View